Proteomic Analysis of Substantia Nigra Reveals Molecular Insights Into the Neuroprotection Effect of Rosmarinic Acid Treatment in MPTP-Induced Mouse Model of Parkinson's Disease.

IF 2.1 4区 生物学 Q3 BIOCHEMICAL RESEARCH METHODS
Sarah Martins Presti-Silva, Lucas Rodrigues-Ribeiro, Vladimir Gorshkov, Frank Kjeldsen, Thiago Verano-Braga, Rita Gomes Wanderley Pires
{"title":"Proteomic Analysis of Substantia Nigra Reveals Molecular Insights Into the Neuroprotection Effect of Rosmarinic Acid Treatment in MPTP-Induced Mouse Model of Parkinson's Disease.","authors":"Sarah Martins Presti-Silva, Lucas Rodrigues-Ribeiro, Vladimir Gorshkov, Frank Kjeldsen, Thiago Verano-Braga, Rita Gomes Wanderley Pires","doi":"10.1002/prca.70006","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Parkinson's disease (PD) is neuropathologically characterized by the progressive degeneration of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc), affecting 10 million people worldwide. Rosmarinic acid (RA), a polyphenol found in plants like rosemary (Rosmarinus officinalis), is known for its intriguing biological properties and potential antioxidant and neuroprotective effects. In a previous study we showed that RA treatment prevented hyperlocomotion in mice with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced parkinsonism and improved the monoaminergic system in healthy animals. However, the molecular mechanisms underlying RA's action in PD remain unclear.</p><p><strong>Experimental design: </strong>In this study, we treated MPTP-induced PD animals (C57BL/6 male mice) with RA orally at a dose of 100 mg/kg for 15 days and examined the proteome of substantia nigra (SN) to identify possible regulatory targets of RA treatment to shed some lights into its neuroprotective effects.</p><p><strong>Results: </strong>Quantitative proteomics revealed that RA treatment regulated proteins associated with oxidative phosphorylation (OXPHOS), glutamatergic synapse, and vesicular cycle signaling pathway. We identified 371 proteins significantly regulated in response to RA administration (255 upregulated and 116 downregulated). Notably, some cellular targets of RA treatment reported here, including mGluR2/mGluR3/EAAT-proteins from the glutamatergic system-and proteins from the Complex I of the electron transport chain are promising targets for therapeutic intervention.</p><p><strong>Conclusions and clinical relevance: </strong>These findings highlight the molecular differences between MPTP-induced PD mice and those treated with RA, providing insights on the molecular basis behind the neuroprotective effects of RA and revealing potential PD signatures that warrant further investigation.</p>","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":" ","pages":"e70006"},"PeriodicalIF":2.1000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PROTEOMICS – Clinical Applications","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1002/prca.70006","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Parkinson's disease (PD) is neuropathologically characterized by the progressive degeneration of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc), affecting 10 million people worldwide. Rosmarinic acid (RA), a polyphenol found in plants like rosemary (Rosmarinus officinalis), is known for its intriguing biological properties and potential antioxidant and neuroprotective effects. In a previous study we showed that RA treatment prevented hyperlocomotion in mice with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced parkinsonism and improved the monoaminergic system in healthy animals. However, the molecular mechanisms underlying RA's action in PD remain unclear.

Experimental design: In this study, we treated MPTP-induced PD animals (C57BL/6 male mice) with RA orally at a dose of 100 mg/kg for 15 days and examined the proteome of substantia nigra (SN) to identify possible regulatory targets of RA treatment to shed some lights into its neuroprotective effects.

Results: Quantitative proteomics revealed that RA treatment regulated proteins associated with oxidative phosphorylation (OXPHOS), glutamatergic synapse, and vesicular cycle signaling pathway. We identified 371 proteins significantly regulated in response to RA administration (255 upregulated and 116 downregulated). Notably, some cellular targets of RA treatment reported here, including mGluR2/mGluR3/EAAT-proteins from the glutamatergic system-and proteins from the Complex I of the electron transport chain are promising targets for therapeutic intervention.

Conclusions and clinical relevance: These findings highlight the molecular differences between MPTP-induced PD mice and those treated with RA, providing insights on the molecular basis behind the neuroprotective effects of RA and revealing potential PD signatures that warrant further investigation.

黑质蛋白质组学分析揭示迷迭香酸对mptp诱导的帕金森病小鼠模型神经保护作用的分子机制。
目的:帕金森病(PD)是一种以黑质致密部(SNpc)多巴胺能(DA)神经元进行性变性为特征的神经病理学疾病,影响全球1000万人。迷迭香酸(RA)是一种在迷迭香(Rosmarinus officinalis)等植物中发现的多酚,以其有趣的生物学特性和潜在的抗氧化和神经保护作用而闻名。在之前的一项研究中,我们发现RA治疗可以预防MPTP(1-甲基-4-苯基-1,2,3,6-四氢吡啶)诱导的帕金森病小鼠的过度运动,并改善健康动物的单胺能系统。然而,RA在PD中的作用的分子机制尚不清楚。实验设计:本研究通过mptp诱导的PD动物(C57BL/6雄性小鼠)口服100 mg/kg剂量的RA治疗15 d,检测黑质(SN)蛋白质组,寻找RA治疗可能的调控靶点,揭示其神经保护作用。结果:定量蛋白质组学显示,RA治疗可调节与氧化磷酸化(OXPHOS)、谷氨酸突触和囊泡周期信号通路相关的蛋白质。我们发现371个蛋白在RA给药后显著调节(255个上调,116个下调)。值得注意的是,本文报道的一些RA治疗的细胞靶点,包括谷氨酸系统的mGluR2/mGluR3/ eaat蛋白和电子传递链复合体I蛋白,都是治疗干预的有希望的靶点。结论和临床意义:这些发现突出了mptp诱导的PD小鼠和RA治疗小鼠之间的分子差异,为RA神经保护作用背后的分子基础提供了见解,并揭示了PD的潜在特征,值得进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
PROTEOMICS – Clinical Applications
PROTEOMICS – Clinical Applications 医学-生化研究方法
CiteScore
5.20
自引率
5.00%
发文量
50
审稿时长
1 months
期刊介绍: PROTEOMICS - Clinical Applications has developed into a key source of information in the field of applying proteomics to the study of human disease and translation to the clinic. With 12 issues per year, the journal will publish papers in all relevant areas including: -basic proteomic research designed to further understand the molecular mechanisms underlying dysfunction in human disease -the results of proteomic studies dedicated to the discovery and validation of diagnostic and prognostic disease biomarkers -the use of proteomics for the discovery of novel drug targets -the application of proteomics in the drug development pipeline -the use of proteomics as a component of clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信